The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two ...
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but ...
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results